Antibody Therapy CRO Services
Cyagen provides comprehensive CRO services for antibody therapy development. Our platform supports you from discovery to validation, leveraging fully human antibody mouse models and cutting-edge AI tools to significantly accelerate your therapeutic breakthroughs.
A Next-Gen Antibody R&D Engine
Our HUGO-Ab™ platform includes three validated product lines – HUGO-Mab™, HUGO-Light™, and
HUGO-Nano™ – supported by flexible licensing or co-development models. Whether your goal is monoclonal,
bispecific, or nanobody discovery, we offer a comprehensive, data-backed solution from target immunization to in
vivo efficacy testing.
{{ item.title }}
{{static_tabs[0].title}}
HUGO-Mab™ – Fully Human Monoclonal Antibody Mice
Generate. Diversify. Translate.
Our next-generation HUGO-Mab™ mice are designed to express fully human
immunoglobulin variable regions across both heavy and light chains. These models recapitulate native
immune development and B cell selection processes, enabling the in vivo generation of high-affinity,
human-sequence monoclonal antibodies. Ideal for developing therapeutic antibodies with broad epitope
coverage, HUGO-Mab™ mice offer validated performance across diverse antigen targets and preclinical
validation settings.
Figure 1. Schematic of antibody gene
structure in HUGO-Mab™ mice, showing full human VH, VK, and VL regions.
Key Features
- Complete humanization of VH, VK, and VL loci
- Multiple strains: C57BL/6, BALB/c, SJL available
- Expresses all human antibody V genes for broad diversity
- Maintains ADCC/CDC functionality via native constant regions
Validation Highlights
Our fully human monoclonal antibody mice exhibit robust immune
development, diverse antibody repertoires, and proven in vivo efficacy.
Figure 2. Growth curve
demonstrating development consistency with WT mice.
Figure 3. Heavy chain VDJ
recombination in naïve B cells reflects rich sequence diversity.
Figure 4. Kappa light chain VJ
recombination patterns align with human profiles.
Figure 5. Lambda light chain VJ
recombination confirms repertoire breadth.
Figure 6. CDR3 length
distribution matches expected human antibody diversity.
Figure 7. Normal immune cell
composition in spleen, matching WT profiles.
Figure 8. Comparable serum titers
after immunization with multiple antigens.
Figure 9. High-affinity binding
to PD-L1 validated via kinetic assays.
Figure 10. T cell activation in
MLR assays confirms functional antibody production.
Figure 11. In vivo tumor
suppression in humanized mouse model.
{{static_tabs[1].title}}
HUGO-Light™ – Human Common Light Chain Mice
Simplify Pairing. Enable Bispecifics.
HUGO-Light™ mice are engineered with fixed human VK light chains to streamline
the production of common light chain antibodies – a critical requirement for bispecific antibody
formats. By minimizing light-heavy chain pairing complexity, these models reduce downstream
screening burden while maintaining robust immunogenicity and high serum titers. With 10 validated
strains expressing distinct VK variants, HUGO-Light™ provides a powerful in vivo system for rapid
bispecific pipeline advancement.
Figure 1. Schematic of antibody gene
structure in HUGO-Light™ mice with fixed human VK and knocked-out mouse light chain
loci.
Key Features
- Fixed human VK light chain (8 mono- and 2 multi-gene variants)
- Compatible with full human VH diversity
- Excellent serum titers post-immunization
- Dual background availability: C57BL/6 and BALB/c
Available Product Variants
- 10 total strains (8 mono-gene VK + 2 multi-gene VK)
- All models constructed using ES cell targeting on C57BL/6NCya background
- Mouse lambda chains knocked out and fixed human kappa chains inserted
Validation Highlights
Explore the immune performance and functional validation of our 10
engineered common light chain mouse models.
Figure 2. VDJ diversity of heavy
chain in naïve splenic B cells.
Figure 3. Balanced immune cell
profiles in both spleen and blood.
Figure 4. Strong serum antibody
titers post-immunization.
Figure 5. Microfluidic B-cell
screening supports high-throughput hit discovery.
Figure 6. ELISA confirms binding
activity of selected anti-VEGF165 clones.
{{static_tabs[2].title}}
HUGO-Nano™ – Fully Human Nanobody Mice
Go Smaller. Target Deeper.
HUGO-Nano™ mice are specially engineered to produce fully human, heavy-chain-only antibodies—ideal for generating nanobody therapeutics with enhanced tissue penetration, thermal stability, and solubility. This platform enables the development of compact, high-specificity binders suitable for CNS targets, intracellular epitopes, or modular bispecific designs. The reduced size and unique structure of nanobodies produced from HUGO-Nano™ open new possibilities in antibody engineering and drug delivery.
Key Features
- Fully human heavy-chain-only antibody generation
- Compact and modular antibody format
- Suitable for CNS delivery, tumor penetration, or bispecific applications
- TurboKnockout® engineered for genomic precision and stability
Validation Highlights
Compact, high-penetration antibody formats start here—backed by
sequence fidelity and in vitro activity
Figure 1. VDJ rearrangement
confirms CH1 deletion and nanobody diversity.
Figure 2. Normal lymphocyte
subsets in peripheral blood.
Figure 3. ELISA shows strong
PD-L1 binding affinity of nanobodies.
{{static_tabs[3].title}}
AbSeek™ – Intelligent Antibody Discovery Platform
Predict. Optimize. Accelerate.
AbSeek™ combines bioinformatics, machine learning, and structural modeling to
empower rational antibody discovery and sequence refinement. From simulating VDJ recombination and
antigen-binding prediction to optimizing developability properties, AbSeek™ integrates seamlessly
with Cyagen’s in vivo platforms. It enables rapid design-build-test cycles, significantly shortening
timelines for lead identification and candidate optimization.
Capabilities Include:
- VDJ recombination simulation
- Structural modeling and binding prediction
- Sequence optimization for affinity, stability, and developability
- Seamless integration with wet-lab validation
{{static_tabs[4].title}}
Supporting Capabilities for Antibody Validation
Enhance. Confirm. Translate.
Cyagen supports your antibody discovery from bench to in vivo validation. Our
immunization services offer flexible antigen formats, tailored adjuvants, and multi-route delivery
strategies to maximize immune response. We also provide comprehensive efficacy validation via tumor
inhibition, immune profiling, and cytokine assays – ensuring that your lead candidates are
functionally robust and translationally relevant.
| Capability | Description |
|---|---|
| Custom Immunization & B-Cell Screening | Tailored immunization protocols for peptides or proteins, combined with single B-cell screening to identify high-affinity, fully human antibodies. |
| In Vivo Functional Validation | PBMC-humanized tumor models, cytokine profiling, and flow cytometry-based analysis to confirm therapeutic efficacy and immune response. |
Our Unique Advantages
Fully Human Antibody Generation
Access three fully validated antibody platforms to generate high-affinity, fully human antibodies for a wide range of therapeutic applications.
Comprehensive In-House Validation
Benefit from rigorous in vivo and in vitro validation, ensuring reliable efficacy and stability for your antibody candidates.
Flexible Engagement Models
Choose from licensing or co-development options that best suit your project's needs and intellectual property goals.
Request a Preclinical CRO Services Consultation
Partner with Cyagen to advance your preclinical studies. Share your project goals with us and receive customized support.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.